Catalent Applied Drug Delivery Institute to Collaborate with Lung Cancer Alliance to Conduct Patient Research

The Catalent Applied Drug Delivery Institute is to collaborate with the Lung Cancer Alliance on patient research in early October. The collaboration will focus on patient and caregiver insights, to better understand the unmet needs of patients when managing lung cancer, also the impact that treatment has on the patient overall, managing other disease states, and daily living.

“The Institute’s mission is dedicated to improving the patient experience through optimized drug delivery. This research is an important first step in developing meaningful patient insights regarding common barriers to adherence and other impacts,” commented Terry Robinson, Executive Director, Catalent Institute. “Our joint goal is to help create better patient outcomes.”

“As the leading non-profit organisation providing support for those touched by lung cancer, we are always looking for innovative ways to make patients’ lives easier,” said Maureen Rigney, LICSW, Director of Community and Support Services for Lung Cancer Alliance. “This partnership with the Catalent Institute aims to do just that. We encourage our community to take part in this survey with the ultimate goal of improving their lives.”